A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria: * Clinical diagnosis of laboratory-supported probable, probable, or definite ALS * Age: 18-70 years * Disease duration: 3-36 months * Forced vital capacity: at least 60% of predicted * ALSFRS-R: at least 30, respiratory items: at least 10 * Decline of ALSFRS-R in the last 3 months before enrollment: 1-8 * Must take riluzole, on a stable dose for at least 30 days prior to baseline visit with no serious side effects. They must continue the riluzole treatment for at least 6 months after enrollment. * Patients of childbearing potential must be using an effective method of birth control * Willing and able to give informed consent Exclusion Criteria: * Familial ALS * Pregnant or nursing women * Patients after tracheotomy or continuous ventilator-dependent (time with non-invasive ventilator more than 22 hours per day for 7 consecutive days.) * After percutaneous endoscopic gastrostomy * Alanine Transaminase (ALT) or Aspartate Transaminase (AST): at least 3 times the upper limit of normal * Abnormal creatinine or urea nitrogen * Severe cardiac disease, pulmonary disease, hematic disease, autoimmune disease, mental disease, dementia and substance abuse * History of malignancy * History of intracranial hemorrhage * History of severe bleeding of digestive tract, lungs, nose and skin * Allergic to fasudil * Participating in other clinical studies or using other investigational drugs at present